local_hospital

HNO-Praxis Landsberg

Address
lock Available on a paid plan

Bacterial Infections and Mycoses

The clinic is investigating ways to reduce the risk of secondary bacterial infections that can follow chronic sinus disease, while also monitoring fungal complications that may arise in the nasal passages.

  • Management of sinusitis complications
  • Evaluation of antimicrobial depot therapy
  • Safety monitoring of biologic agents

HNO‑Praxis Landsberg collaborates with local specialists to ensure comprehensive care for patients at risk of infection.

Immune System Diseases

Research at the site emphasizes immune‑modulating strategies for conditions such as allergic rhinitis and nasal polyps, including the use of targeted antibodies to calm inflammatory pathways.

  • Anti‑IL‑33 monoclonal antibody studies
  • Grass pollen sublingual immunotherapy in children
  • Biologic approaches for nasal polyp reduction

The team at HNO‑Praxis Landsberg aims to improve quality of life by addressing the underlying immune dysfunction.

Respiratory Tract Diseases

The primary focus is on chronic rhinosinusitis and seasonal allergic rhinitis, evaluating innovative delivery systems to relieve the key symptoms of nasal congestion, discharge, and loss of smell.

  • Depot sinus implant efficacy
  • Pediatric grass pollen allergy treatment
  • Nasal polyp size reduction studies

Patients benefit from the expertise of the HNO‑Praxis Landsberg team, which integrates advanced therapeutic options into routine ENT care.

Site Overview

assignment
3
connected trials
corporate_fare
3
sponsors
science
13
IMPs

Activity Indicator

Last 6 months

0
Trials started
0
Trials started 6–12 months ago
3
Total trials linked
Moderately Active
trending_flatStable0%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
1
Sponsors (total)
3
Active sponsors
1

Sponsor Network

Top 1 by active trials.

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

No repeated partnerships found.

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 2 161 other sites in Germany

description
Trial volume
3
Outperforms 61% of sites
public
Therapeutic diversity
3areas
Outperforms 79% of sites
groups
Sponsor diversity
3sponsors
Outperforms 65% of sites

Therapeutic Area Benchmark — Germany

Select a therapeutic area to compare against other sites in Germany.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Germany

Market Share

Country: Germany

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in HNO-Praxis Landsberg

lock Showing 1 of 3 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
Efficacy and Safety Evaluation of PQ Grass 27600 SU in Pediatric Patients with Grass Pollen-Induced Seasonal Allergic Rhinitis/RhinoconjunctivitisAllergy Therapeutics (UK) LimitedPhase IIIRecruitingSep 2024

IMP list

lock Showing 1 of 13 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
12 Grass Pollen Mixture1Unknown2024-09-062024-09-06

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.